

EMA/36089/2017

European Medicines Agency decision P/0023/2017

of 13 February 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ciprofloxacin (hydrochloride) (EMA-001563-PIP02-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0023/2017

of 13 February 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ciprofloxacin (hydrochloride) (EMA-001563-PIP02-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Aradigm Limited on 25 January 2016 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 December 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ciprofloxacin (hydrochloride), nebuliser solution, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ciprofloxacin (hydrochloride), nebuliser solution, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for ciprofloxacin (hydrochloride), nebuliser solution, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Aradigm Limited, 12 New Fetter Lane, EC4A 1JP – London, United Kingdom.

EMA/PDCO/644910/2016
London, 16 December 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001563-PIP02-15

Scope of the application

Active substance(s):

Ciprofloxacin (hydrochloride)

Condition(s):

Treatment of chronic pulmonary infections caused by *Pseudomonas aeruginosa*

Pharmaceutical form(s):

Nebuliser solution

Route(s) of administration:

Inhalation use

Name / corporate name of the PIP applicant:

Aradigm Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Aradigm Limited submitted for agreement to the European Medicines Agency on 25 January 2016 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 1 March 2016.

Supplementary information was provided by the applicant on 26 September 2016. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report
 - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
 - to grant a deferral in accordance with Article 21 of said Regulation;
 - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The divergent position(s) is (are) appended to this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of chronic pulmonary infections caused by *Pseudomonas aeruginosa*

The waiver applies to:

- the paediatric population from birth to less than 4 years;
- nebuliser solution, inhalation use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of chronic pulmonary infections caused by *Pseudomonas aeruginosa*

2.1.1. Indication(s) targeted by the PIP

Treatment of cystic fibrosis related bronchiectasis associated with *Pseudomonas aeruginosa* infection

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Nebuliser solution

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	3	Study 1 Safety, tolerability and PK study of Ciprofloxacin (hydrochloride) nebuliser solution in cystic fibrosis children from 4 to less than 18 years (and adults) with chronic lung infections due to <i>Pseudomonas aeruginosa</i>

Area	Number of measures	Description
		Study 2 Randomised, active controlled, multicentre study to assess the efficacy, safety and tolerability of Ciprofloxacin (hydrochloride) nebuliser solution in cystic fibrosis (CF) patients from 4 to less than 18 years of age with chronic lung infection due to <i>Pseudomonas aeruginosa</i> Study 3 Extension study of Ciprofloxacin (hydrochloride) nebuliser solution in CF patients with chronic <i>Pseudomonas aeruginosa</i> infection previously enrolled in Study 2
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes